B. Riley Wealth Advisors Inc. Purchases New Stake in Hims & Hers Health, Inc. (NYSE:HIMS)

B. Riley Wealth Advisors Inc. purchased a new stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 8,272 shares of the company's stock, valued at approximately $200,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Crewe Advisors LLC bought a new position in shares of Hims & Hers Health during the fourth quarter worth approximately $28,000. Blume Capital Management Inc. lifted its stake in shares of Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after purchasing an additional 600 shares during the period. Smartleaf Asset Management LLC increased its position in Hims & Hers Health by 4,415.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock valued at $36,000 after buying an additional 1,413 shares in the last quarter. Summit Securities Group LLC bought a new stake in Hims & Hers Health in the 4th quarter valued at about $38,000. Finally, US Bancorp DE increased its holdings in Hims & Hers Health by 346.7% during the 4th quarter. US Bancorp DE now owns 1,943 shares of the company's stock worth $47,000 after purchasing an additional 1,508 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company's stock.

Insiders Place Their Bets

In other news, insider Patrick Harrison Carroll sold 23,287 shares of the business's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $34.31, for a total value of $798,976.97. Following the completion of the transaction, the insider now directly owns 209,661 shares in the company, valued at approximately $7,193,468.91. The trade was a 10.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Soleil Boughton sold 3,236 shares of the company's stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $27.77, for a total transaction of $89,863.72. Following the completion of the transaction, the insider now owns 170,285 shares of the company's stock, valued at approximately $4,728,814.45. This trade represents a 1.86% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 617,367 shares of company stock worth $25,227,888 over the last 90 days. Corporate insiders own 13.71% of the company's stock.

Hims & Hers Health Trading Down 1.5%

NYSE HIMS traded down $0.79 during trading hours on Thursday, reaching $52.82. 36,727,389 shares of the company traded hands, compared to its average volume of 20,543,983. The stock has a market capitalization of $11.82 billion, a PE ratio of 120.05 and a beta of 2.09. Hims & Hers Health, Inc. has a 12 month low of $13.47 and a 12 month high of $72.98. The company has a 50 day moving average of $41.72 and a two-hundred day moving average of $36.90.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.08. The company had revenue of $586.01 million during the quarter, compared to analyst estimates of $535.21 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business's revenue for the quarter was up 110.7% on a year-over-year basis. During the same quarter last year, the firm posted $0.05 EPS. On average, equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently commented on HIMS shares. Needham & Company LLC upped their price objective on Hims & Hers Health from $61.00 to $65.00 and gave the company a "buy" rating in a research note on Wednesday. Wall Street Zen raised Hims & Hers Health from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. Piper Sandler restated a "neutral" rating and issued a $39.00 price objective (up from $35.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. Truist Financial reduced their price target on shares of Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating for the company in a research report on Thursday, April 10th. Finally, Canaccord Genuity Group boosted their price objective on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a research report on Wednesday, February 19th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $38.00.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.